Physician profile
Inder P Singh
NPI 1063430023
$2,487,519.36
in general payments reported to CMS, 2019-2025
52 companies · $454K in 2025
The $454K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $330K · 2020: $264K · 2021: $332K · 2022: $380K · 2023: $353K · 2024: $375K · 2025: $454K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $612K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $231K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $175K · Travel and Lodging: $89K · Food and Beverage: $57K · Honoraria: $19K · Gift: $36.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $611,658.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $231,164.99 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $174,575.40 |
| Travel and Lodging | $88,552.43 |
| Food and Beverage | $56,775.39 |
| Honoraria | $19,200.00 |
| Gift | $36.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $406,608.22 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Allergan, INC. | $375,409.65 | 2019-2022 | |
| Glaukos Corporation | $216,301.39 | 2019-2025 | Idose, Travoprost Intraocular Implant - Idose, Idose Tr |
| Lumibird Medical INC. | $195,231.35 | 2019-2025 | |
| Alcon Vision LLC | $182,026.78 | 2019-2025 | Hydrus Microstent, Rocklatan, Tryptyr |
| Abbvie INC. | $175,186.53 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $127,146.18 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $79,606.70 | 2019-2025 | Forum, Cirrus Hd-Oct, Forum Glaucoma Workplace |
| Reichert, INC. | $78,920.50 | 2019-2025 | Tono-Vera Tonometer US Starter Kit Human Rechargable |
| Sight Sciences, INC. | $77,566.56 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Research LLC | $77,207.01 | 2022-2025 | Rocklatan, Rhopressa, Hydrus Microstent |
| Tarsus Pharmaceuticals, INC. | $72,475.90 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $64,425.96 | 2019-2025 | Dextenza |
| Nova Eye, INC. | $62,376.83 | 2022-2023 | |
| Aerie Pharmaceuticals, INC. | $45,983.18 | 2019-2021 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $43,135.72 | 2019-2025 | Streamline, Kahook Dual Blade, Clearpath |
| Oyster Point Pharma, INC. | $36,683.25 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Carl Zeiss Meditec Cataract Technology INC. | $30,177.29 | 2021-2024 | |
| Ivantis, INC | $29,321.30 | 2019-2021 | |
| Ellexiscience | $20,500.00 | 2019 | |
| Eyepoint US, INC. | $16,304.38 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $12,715.08 | 2019-2023 | |
| Carl Zeiss Meditec USA, INC. | $10,716.55 | 2021-2025 | Visumax, Cirrus Hd-Oct, Humphrey Hfa |
| Rayner Intraocular Lenses Limited | $10,272.94 | 2022-2025 | Omidria, Rayone Spheric, Rayone Emv |
| Shire North American Group INC | $8,596.28 | 2019 | |
| Harrow Eye, LLC | $6,225.12 | 2023-2025 | Iheezo, Vevye, Triesence |
| Kala Pharmaceuticals, INC. | $6,056.63 | 2019-2022 | |
| Dompe US, INC. | $5,982.98 | 2019-2025 | Oxervate |
| Rxsight INC | $5,054.81 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Regeneron Pharmaceuticals, INC. | $2,040.00 | 2025 | Eylea |
| Horizon Therapeutics Plc | $1,849.68 | 2021-2023 | Tepezza |
| Thea Pharma INC. | $1,497.49 | 2023-2025 | Iyuzeh |
| Beaver-Visitec International, INC. | $930.88 | 2022-2025 | |
| Microsurgical Technology, INC. | $750.00 | 2023 | |
| Sun Pharmaceutical Industries INC. | $577.27 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Biotissue Holdings INC. | $253.86 | 2021-2025 | |
| Quidel Corporation | $201.85 | 2021-2022 | |
| Amgen INC. | $191.13 | 2024-2025 | Tepezza |
| The Cameron-Ehlen Group, INC. | $182.36 | 2019-2022 | |
| Tactile Systems Technology INC | $146.19 | 2024 | Flexitouch Plus, Entre Plus |
| Regeneron Healthcare Solutions, INC. | $109.36 | 2023-2025 | Eylea Hd |
| Apellis Pharmaceuticals, INC. | $107.43 | 2022-2025 | Syfovre |
| Lensar, INC. | $96.99 | 2021 | |
| Omeros Corporation | $92.06 | 2019-2021 | |
| Astellas Pharma US INC | $64.09 | 2024-2025 | Izervay |
| Eyevance Pharmaceuticals LLC | $55.77 | 2019-2021 | |
| Katena Products, INC. (Dba Corza Medical) | $51.60 | 2019 | |
| Tearlab Corp | $28.90 | 2022 | |
| Oculus Surgical INC. | $25.82 | 2025 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.40 | 2019 | |
| Iridex Corporation | $14.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$180,430.07 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.